HHS’ new vaccine panel backs RSV shot, rejects thimerosal in flu vaccines

Becker’s Hospital Review – Thursday, June 26, 2025
By Paige Twenter

On June 26, HSS’ newly formed Advisory Committee on Immunization Practices voted 5-2 to recommend Merck’s respiratory syncytial virus monoclonal antibody drug and against an ingredient in some flu vaccines.

The RSV drug in question, clesrovimab, is recommended for infants younger than 8 months. It was approved in early June, making it the second FDA-approved RSV preventive therapy for young children. The first, AstraZeneca’s Beyfortus (nirsevimab-alip), received FDA approval in July 2023 for children 24 months and younger.

Click here to read the entire article.